6 Best Peptides for Belly Fat

What to Know Before Choosing a Peptide for Belly Fat

Belly fat is not one thing. The fat that sits beneath your skin, the kind you can pinch, behaves differently from visceral fat, the deeper fat surrounding your internal organs. That distinction matters here because some peptides on this list work specifically on visceral fat through hormonal signaling, while others reduce overall body weight and bring belly fat down as a downstream effect. A few work directly on fat cells through a separate mechanism entirely. Knowing which approach a compound uses is the first step toward understanding whether it fits your actual goal.

A peptide earned a slot on this list because people genuinely use it or are actively discussing using it for belly fat reduction. That test is not about FDA approval status, and it is not about how much clinical trial data exists. FDA-approved compounds, telemedicine-prescribed medications, and research-only peptides discussed in functional medicine and community protocols are all eligible, and evidence strength is stated honestly rather than used as a filter. Some entries here rest on large randomized controlled trials. Others rest mostly on user-reported experience, and that is described plainly when it is the case.

The entries are numbered because the title needs a count, but the numbers reflect how prominently each compound appears in research and real-world use, not a verdict that one is better than another for you. Read each entry on its own terms.

One framing note before the list: no topical or oral "belly fat peptide" meaningfully reduces abdominal fat. Every compound here is injectable, and the ones with real evidence behind them are used under medical supervision. Diet and exercise remain foundational regardless of which compound someone adds.

1. Tesamorelin: The Only Peptide with RCT Data for Visceral Fat

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, the signal your hypothalamus sends to the pituitary to trigger a pulse of growth hormone. When you take tesamorelin, it binds to the same receptors your natural GHRH uses, prompting your pituitary to release growth hormone in the same pulsatile, physiologic pattern your body would produce on its own. That growth hormone then travels to the liver and peripheral tissues, drives IGF-1 production, and the resulting hormonal environment preferentially mobilizes visceral adipose tissue, the deep fat surrounding your organs, rather than the subcutaneous fat sitting just beneath your skin.

That mechanism makes tesamorelin the only peptide on this list with a specific, direct approach aimed at the visceral fat depot. Every other compound here either reduces overall body weight, bringing belly fat down as a consequence, or works through a lipolytic pathway that has not been validated in large human trials the way tesamorelin has.

The clinical evidence is the most substantial you will find in this field. Multiple double-blinded, randomized controlled trials have studied tesamorelin, with primary treatment periods of 26 weeks and long-term follow-up out to four years. In those trials, the treatment group saw roughly a 15 percent reduction in visceral fat area while the placebo group saw a modest increase. The reduction in visceral fat area in the treatment group was roughly 34 square centimeters, compared to an increase of around 8 square centimeters in the placebo group. Approximately 70 percent of people treated with tesamorelin achieved what the researchers defined as a therapeutic response, at least an 8 percent reduction in visceral fat. Subcutaneous fat, the pinchable kind, did not change meaningfully in either group. Tesamorelin reduces deep fat selectively, not surface fat and not overall body weight.

The limitations are worth naming directly. The FDA approved tesamorelin specifically for HIV-associated lipodystrophy, the visceral fat accumulation that can develop as a side effect of HIV treatment. Its approval does not extend to general obesity or belly fat reduction in people without HIV. The trial data comes almost entirely from that population, which limits how confidently the results generalize to healthy adults pursuing fat loss. Off-label prescribing happens in functional medicine settings, but access is significantly more restricted than for the GLP-1 medications below, and it is not widely available through general telemedicine platforms. People who have used it through functional medicine practitioners report that it requires a months-long commitment and targets hard, deep gut fat rather than surface fat, which aligns with what the trials show.

If your goal is specifically reducing visceral fat and you have access to a functional medicine provider willing to prescribe it off-label, tesamorelin is the compound with the most honest clinical support for that specific job.

2. Semaglutide: The Most Widely Used Option for Overall Fat Loss

Semaglutide belongs to a class called GLP-1 receptor agonists. GLP-1 is a hormone your gut produces after you eat, and it signals your brain that food has arrived, increasing satiety and reducing appetite. Semaglutide mimics that signal, binding to GLP-1 receptors in the hypothalamus, the pancreas, and the gastrointestinal tract. The result is reduced appetite, slower gastric emptying so food moves through your stomach more slowly and you feel full longer, and more controlled blood sugar through stimulated insulin secretion. It does not go directly after fat cells. It works on appetite regulation, and belly fat comes down because you are eating less overall and your body draws on stored fat for energy.

The clinical evidence for semaglutide is extensive. Large-scale randomized controlled trials have shown average total body weight loss of roughly 16 to 22 percent over the course of treatment, placing it among the most effective single pharmacological agents for weight management. Belly fat reduction happens proportionally alongside overall weight loss, not through any targeted visceral mechanism.

Semaglutide is FDA-approved for chronic weight management under the brand name Wegovy, with eligibility criteria that include a BMI of 30 or higher, or 27 or higher with at least one weight-related health condition. It is also FDA-approved for type 2 diabetes under the brand name Ozempic, and that version is frequently used off-label for weight management. It is the most widely accessible compound on this list, available through telemedicine platforms with a prescription and standard medical screening.

The trade-offs are real. Semaglutide works through appetite suppression, and when you stop taking it, appetite tends to return toward baseline, which means the weight often follows. The most common side effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation, particularly during dose escalation. There is also a black box warning regarding medullary thyroid carcinoma risk observed in animal studies, and the medication is contraindicated in people with a personal or family history of that cancer or of a related condition called MEN2. Medical screening before starting is not optional.

For most people exploring peptides for belly fat, semaglutide is the most realistic entry point: FDA-approved, broadly accessible, and backed by the strongest general weight loss data in the field.

3. Tirzepatide: The Dual-Mechanism Option with Superior Weight Loss Outcomes

Tirzepatide does what semaglutide does and adds a second mechanism on top. Where semaglutide activates only the GLP-1 receptor, tirzepatide activates both the GLP-1 receptor and the GIP receptor. GIP stands for glucose-dependent insulinotropic polypeptide, another gut hormone involved in appetite regulation and fat metabolism. Activating both receptors together produces additive effects on satiety and metabolic regulation that neither receptor produces on its own.

In head-to-head comparisons with semaglutide, tirzepatide has generally produced greater weight loss. Clinical trials have shown average total body weight loss of around 21 percent over 72 weeks, and some studies have reported numbers beyond that at the highest doses. Like semaglutide, it reduces belly fat as a downstream effect of overall weight loss rather than through a targeted visceral mechanism. The dual activation of GIP receptors does appear to carry additional effects on fat metabolism beyond appetite suppression alone, though the clinical significance of that specific pathway for visceral fat specifically is still being worked out in ongoing research.

Tirzepatide is FDA-approved for chronic weight management under the brand name Zepbound, for type 2 diabetes under the brand name Mounjaro, and also for obesity-related sleep apnea. Access is similar to semaglutide: widely available through telemedicine with a prescription and medical screening. The side effect profile is also similar, with gastrointestinal symptoms being the most common complaints during dose escalation and the same black box warning regarding thyroid cancer risk applying here as well.

The choice between semaglutide and tirzepatide is one where individual response matters, and both require ongoing use to maintain results. People who have tried both often report that tirzepatide produces meaningfully greater appetite suppression, though individual variation is significant. For someone whose primary obstacle is appetite and overall caloric intake, tirzepatide is where the evidence currently points for maximum effect.

4. AOD-9604: For Direct Lipolysis Without the GH Axis

AOD-9604 is derived from the C-terminal region of human growth hormone, specifically the fragment spanning amino acids 176 to 191. That fragment is the portion of the growth hormone molecule associated with fat metabolism. The idea behind AOD-9604 is to isolate that fat-burning activity without the rest of growth hormone's effects on blood sugar, IGF-1 levels, and growth signaling. In laboratory and animal work, AOD-9604 activates lipolysis, the breakdown of stored fat in fat cells, and inhibits lipogenesis, the formation of new fat, while leaving insulin sensitivity and IGF-1 levels largely unaffected. It works directly on fat cells rather than through upstream hormonal signaling.

The clinical evidence is significantly thinner than what exists for tesamorelin or the GLP-1 medications. One published trial showed a reduction in waist circumference in obese adults, and the compound received Generally Recognized as Safe status as a food ingredient in the United States, connected to earlier efforts to develop it as a weight loss drug. Those development efforts did not produce an approved pharmaceutical, and AOD-9604 is not FDA-approved for weight loss or fat reduction. It sits in a legal and regulatory gray area, used off-label through some functional medicine and compounding pharmacy channels and sold online as a research chemical. The research chemical route is flagged consistently as unsafe for self-injection due to the absence of purity testing and quality control.

In functional medicine and wellness clinic settings, AOD-9604 is used for abdominal fat support and frequently combined with other peptides in stacking protocols. The evidence base here is experiential rather than clinical. Practitioners and users describe it as a targeted lipolytic agent that avoids the blood sugar effects associated with GH-raising compounds, a distinction that matters for people who want to avoid anything that touches insulin signaling. What does not exist is a body of large, well-controlled human trials confirming that the effects seen in earlier research translate to meaningful fat reduction in typical users. That gap is worth understanding clearly before pursuing this compound.

5. CJC-1295 and Ipamorelin: The Stacked GH Secretagogue Approach

CJC-1295 and ipamorelin are almost always discussed together because they are almost always used together. CJC-1295 is a growth hormone-releasing hormone analog, working through the same upstream pituitary pathway as tesamorelin, though with a different molecular profile and a significantly longer half-life. Ipamorelin is a growth hormone secretagogue that stimulates GH release through a different receptor pathway, the ghrelin receptor, rather than the GHRH pathway. When you combine them, you get growth hormone release stimulated simultaneously through two complementary mechanisms, which produces a larger and more sustained GH pulse than either compound generates on its own.

Elevated growth hormone supports improved body composition through lipolysis and lean muscle preservation. That is the physiological rationale for using this combination for belly fat, and it is a plausible one given what growth hormone does in the body. The challenge is that the human trial data specifically for fat loss with this combination is limited. No large randomized controlled trials have studied CJC-1295 and ipamorelin together for belly fat reduction. What exists is use in functional medicine settings, a mechanistically coherent rationale based on GH's known lipolytic properties, and user-reported results from people who have run protocols through compounding pharmacies and functional medicine providers.

Compared to tesamorelin, this stack is less specifically targeted at visceral fat. Tesamorelin's tight pulsatile mechanism and its specific trial data make it the more defensible choice when visceral fat reduction is the explicit goal. The CJC-1295 and ipamorelin combination is more broadly used for general body composition improvement, fat loss alongside muscle preservation, rather than as a pure visceral fat intervention. Both compounds are available through functional medicine providers and compounding pharmacies. Neither is FDA-approved, and both are sold online as research chemicals with the same purity and safety concerns that attach to that market.

6. MOTS-c: An Emerging Mitochondrial Approach

MOTS-c stands apart from every other compound on this list in a fundamental way: it is encoded within mitochondrial DNA rather than nuclear DNA. That makes it part of a newly recognized class of mitochondria-derived peptides that regulate metabolism at the cellular level rather than through upstream hormonal signaling. Where tesamorelin works by prompting the pituitary to release more growth hormone, and where GLP-1 agonists work by reducing appetite through brain signaling, MOTS-c works downstream, inside the cell, by activating AMPK.

AMPK stands for AMP-activated protein kinase, and the easiest way to think about it is as a cellular energy sensor that functions like a metabolic switch. When AMPK is active, it shifts the cell toward burning stored energy rather than accumulating it, improving glucose uptake, enhancing fatty acid oxidation, and reducing the kind of metabolic dysfunction associated with visceral fat accumulation. In cell studies and early animal models, MOTS-c has shown reductions in visceral fat and improvements in insulin sensitivity through this mechanism.

The honest state of the evidence is that no published human clinical trials have studied MOTS-c for belly fat reduction as of 2026. The research is early and promising at the cell and animal level, but the translation to human physiology has not been established in controlled research. MOTS-c is not FDA-approved and is not available through standard clinical or telemedicine channels. It exists in community discussions and emerging research as an experimental compound that people are watching, and in some cases using, based on its mitochondrial mechanism and the early data. That is the context to hold it in: an intellectually compelling emerging compound with a real mechanistic rationale and a very early evidence base.

How These Peptides Compare

Frequently Asked Questions

Is there a peptide that specifically targets belly fat rather than causing general weight loss?

Tesamorelin is the only compound on this list with published human trial data showing selective visceral fat reduction rather than general weight loss. It works through growth hormone signaling to mobilize deep abdominal fat without meaningfully changing subcutaneous fat or overall body weight. The GLP-1 medications, semaglutide and tirzepatide, reduce belly fat as a proportional consequence of significant overall weight loss, not through a targeted mechanism. AOD-9604 is designed around a direct lipolytic mechanism but lacks the clinical trial record to confirm that mechanism translates at scale in humans.

Do you need a prescription for these peptides?

Three of the six compounds on this list require a prescription and are FDA-approved for specific indications: tesamorelin, semaglutide, and tirzepatide. Semaglutide and tirzepatide are widely accessible through telemedicine platforms with standard medical screening. Tesamorelin is more restricted, typically requiring a specialist or functional medicine provider. AOD-9604, CJC-1295, and ipamorelin are not FDA-approved for fat loss and are obtained through compounding pharmacies or, through an unsafe route, as unregulated research chemicals online. MOTS-c is available only through research channels as of 2026.

How long does it take to see results with these compounds?

The timeline varies considerably by compound and by how it works. In clinical trials, tesamorelin showed measurable visceral fat changes over 26 weeks of daily use. The GLP-1 medications produce weight loss more steadily over months, with meaningful results typically appearing after several weeks of treatment and continuing to accumulate over a year or more. For AOD-9604 and the CJC-1295 and ipamorelin stack, community-reported timelines vary widely and are not supported by controlled data, so any timeline there reflects what users report rather than measured outcomes.

Are these compounds safe to use?

The FDA-approved options, semaglutide and tirzepatide, have the most thoroughly studied safety profiles, with gastrointestinal symptoms such as nausea and changes in bowel habits being the most common complaints, particularly during dose escalation. Both carry a black box warning regarding thyroid cancer risk observed in animal studies. Tesamorelin has a reasonable safety signal from its clinical trials. The non-approved compounds, AOD-9604, CJC-1295, ipamorelin, and MOTS-c, carry greater uncertainty because they have not undergone the same scale of human safety evaluation, and purchasing any of them through unregulated online research chemical channels adds significant contamination and infection risk beyond that.

Can diet and exercise alone accomplish what these compounds do?

For subcutaneous belly fat, a consistent caloric deficit combined with resistance training and aerobic exercise is the most evidence-supported approach available and remains foundational regardless of whether any compound is added. Visceral fat also responds meaningfully to lifestyle intervention, particularly aerobic exercise and caloric restriction. What the compounds on this list add, depending on which one, is either a targeted hormonal intervention for visceral fat that diet and exercise do not replicate, or a pharmacological reduction in appetite that makes maintaining a caloric deficit substantially easier. Even people in clinical trials using these medications consistently reported that diet and lifestyle remained central to their results.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for belly fat in one place.